Bicycle Therapeutics (BCYC) Net Margin (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Net Margin came in at 8002.07% in Q2 2026, down 529823.0% YoY from N/an in Q2 2025, and down 16.69% on a QoQ basis from 6857.38% in Q1 2026.
Powered by 
Analysis
Bicycle Therapeutics (BCYC) Net Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Net Margin data on file, last reported at 8002.07% in Q2 2026.
- Quarterly Net Margin fell 529823.0% year-over-year to 8002.07% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 311.11% (up 94589.0% YoY) and the FY2025 annual result came in at 301.66%, up 17752.0% from the prior year.
- Net Margin eased to 8002.07% in Q2 2026, from 6857.38% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 42.03% in Q4 2025 to a low of 8002.07% in Q2 2026.
- A 5-year average of 1557.96% and a median of 755.98% in 2022 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2025 — Net Margin surged 139477 bps — and 2026, when it slumped 624844 bps.
- Tracing BCYC's Net Margin over 5 years: stood at 356.88% in 2022, then tumbled by 158 bps to 921.01% in 2023, then slumped by 52 bps to 1398.44% in 2024, then surged by 97 bps to 42.03% in 2025, then sank by 18940 bps to 8002.07% in 2026.
- The last three Net Margin figures came in at 8002.07% (Q2 2026), 6857.38% (Q1 2026), and 42.03% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Bicycle Therapeutics | 299.81 Mn | 299.81 Mn | - | -8,002.07% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8,002.07% |
| Mar 31, 2026 | -6,857.38% |
| Dec 31, 2025 | -42.03% |
| Sep 30, 2025 | -503.66% |
| Jun 30, 2025 | -2,703.84% |
| Mar 31, 2025 | -608.94% |
| Dec 31, 2024 | -1,398.44% |
| Sep 30, 2024 | -1,898.43% |
| Jun 30, 2024 | -425.30% |
| Mar 31, 2024 | -136.01% |
| Dec 31, 2023 | -921.01% |
| Sep 30, 2023 | -932.32% |
| Jun 30, 2023 | -373.81% |
| Mar 31, 2023 | -797.88% |
| Dec 31, 2022 | -356.88% |
| Sep 30, 2022 | -932.47% |
| Jun 30, 2022 | -319.38% |
| Mar 31, 2022 | -714.09% |
| Dec 31, 2021 | -1,127.31% |
| Sep 30, 2021 | -338.75% |